Novo Nordisk A/S $NVO Shares Sold by Marietta Investment Partners LLC

Marietta Investment Partners LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 16.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,999 shares of the company’s stock after selling 16,311 shares during the quarter. Marietta Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $4,223,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in NVO. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. WealthCollab LLC raised its holdings in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NVO. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Wolfe Research began coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

NVO stock opened at $42.06 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a 50 day simple moving average of $41.35 and a 200-day simple moving average of $46.24. The firm has a market capitalization of $187.78 billion, a PE ratio of 9.87, a price-to-earnings-growth ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched the Wegovy pill in the UAE, marking its first market outside the U.S. and signaling the start of a broader international rollout for its obesity franchise. Reuters article
• Positive Sentiment: Novi Health announced a partnership with Novo Nordisk to expand structured weight-care support in Singapore, which could help improve patient access and treatment adoption in another growth market. Yahoo Finance article
• Positive Sentiment: Danske Bank raised Denmark’s GDP forecast to 3.7%, citing export strength supported by demand for Novo Nordisk products, underscoring the company’s importance to the Danish economy. Financial Post article
• Neutral Sentiment: Commentary suggested there may be “light at the end of the tunnel” for Novo Nordisk, but it was opinion-based rather than a new fundamental update. Motley Fool article
• Negative Sentiment: Eli Lilly won back CVS Health, reversing part of Novo Nordisk’s advantage in GLP-1 access and highlighting intensifying competition in the obesity drug market. MarketBeat article
• Negative Sentiment: ASML’s surge to record valuation drew attention to Novo Nordisk’s prior peak as Europe’s most valuable stock, reinforcing how far NVO has fallen from its high-water mark. Yahoo Finance article

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.